摘要
目的评价糖皮质激素联合抗甲状腺药物与单用抗甲状腺药物治疗Graves病的有效性及安全性。方法手工及电脑检索国内外糖皮质激素与抗甲状腺药物治疗Graves病的随机对照研究,采用Cochrane质量评价标准进行定量化质量评估,采用Rev Man 5.3进行系统统计分析。结果纳入10项研究,糖皮质激素与抗甲状腺药物联合组可有效降低FT3,FT4,T4水平,差异有统计学意义(P<0.01),对T3,TSH无明显差异。糖皮质激素联合抗甲状腺药物组不良反应发生率较低。结论糖皮质激素联合抗甲状腺药物治疗Graves病对FT3,FT4,T4水平的改善有较好的疗效,且安全性更高。
OBJECTIVE To evaluate the glucocorticoid associated with anti-thyroid drugs and anti-thyroid drugs alone to treatment Graves＇ disease is whether effective and safety. METHODS All randomized controlled trials（RCTs） comparing glucocorticoid associated anti-thyroid drugs with anti-thyroid drugs alone for the management of Graves＇ disease were identified by manual and computer retrieval. To evaluate by the Cochrane quality evaluation standard, and statistical analysis using Revman5.3 system. RESULTS In 10 study, glucocorticoid associated with anti-thyroid drugs group can effectively reduce the FT3, FT4, T4 levels, there were significant difference（P〈0.01）. But the T3, TSH levels had no obvious difference. Glucocorticoid associated with anti-thyroid drugs group has a lower incidence of adverse reactions. CONCLUSION Glucocorticoid associated with anti-thyroid drugs to treat Graves＇ disease has a good curative effect on the improvement of the FT3, FT4, T4. And it security is higher.
作者
马朝
张伟
梅思斌
黄巧玲
MA Zhao ZHANG Wei MEI Sibin HUANG Qiaoling(Hangzhou Third Hospital, Hangzhou 310009, China Hangzhou Institute for Food and Drug Control, Hangzhou 310022, China Zhejiang University School of Medicine, Hangzhou 310058, China)
出处
《中国现代应用药学》
CAS
CSCD
2016年第10期1318-1323,共6页
Chinese Journal of Modern Applied Pharmacy
